David Nierengarten
Stock Analyst at Wedbush
(3.67)
# 790
Out of 4,964 analysts
201
Total ratings
45.34%
Success rate
8.29%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $9.30 | +168.82% | 1 | Aug 18, 2025 | |
| GBIO Generation Bio Co. | Downgrades: Neutral | $7 | $6.35 | +10.24% | 9 | Aug 13, 2025 | |
| XNCR Xencor | Maintains: Outperform | $31 → $26 | $8.02 | +224.39% | 7 | Aug 7, 2025 | |
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $2.00 | -80.00% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $707.96 | +0.99% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.61 | +204.71% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $12.10 | +81.82% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $2.95 | +69.49% | 9 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.13 | +18.46% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $11.42 | -12.43% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $11.91 | +126.70% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $33.70 | +0.89% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $9.95 | +231.66% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.90 | +121.34% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.12 | +346.43% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $12.03 | +157.80% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $20.40 | +96.08% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $37.85 | +137.78% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $34.47 | +36.35% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $76.18 | +50.96% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.55 | +169.16% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.25 | +95.12% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $15.20 | +163.16% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $17.13 | +162.70% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.87 | +434.76% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.27 | +450.46% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $59.97 | -4.95% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.37 | -19.16% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.43 | +249.85% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $16.86 | +238.08% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $7.63 | +2,193.58% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.79 | +13,092.61% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $7.81 | +668.25% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $9.07 | +109.48% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $30.08 | +149.34% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.42 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.56 | - | 3 | Nov 20, 2017 |
BridgeBio Oncology Therapeutics
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $9.30
Upside: +168.82%
Generation Bio Co.
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $6.35
Upside: +10.24%
Xencor
Aug 7, 2025
Maintains: Outperform
Price Target: $31 → $26
Current: $8.02
Upside: +224.39%
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $2.00
Upside: -80.00%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $707.96
Upside: +0.99%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.61
Upside: +204.71%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $12.10
Upside: +81.82%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $2.95
Upside: +69.49%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.13
Upside: +18.46%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $11.42
Upside: -12.43%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $11.91
Upside: +126.70%
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $33.70
Upside: +0.89%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $9.95
Upside: +231.66%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.90
Upside: +121.34%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.12
Upside: +346.43%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $12.03
Upside: +157.80%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $20.40
Upside: +96.08%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $37.85
Upside: +137.78%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $34.47
Upside: +36.35%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $76.18
Upside: +50.96%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $8.55
Upside: +169.16%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.25
Upside: +95.12%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $15.20
Upside: +163.16%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $17.13
Upside: +162.70%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.87
Upside: +434.76%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.27
Upside: +450.46%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $59.97
Upside: -4.95%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $12.37
Upside: -19.16%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.43
Upside: +249.85%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $16.86
Upside: +238.08%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $7.63
Upside: +2,193.58%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.79
Upside: +13,092.61%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $7.81
Upside: +668.25%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $9.07
Upside: +109.48%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $30.08
Upside: +149.34%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.42
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.56
Upside: -